Published in Arthritis Care Res (Hoboken) on February 01, 2010
Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis. Nat Rev Rheumatol (2011) 1.48
Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies. JAMA (2011) 1.41
Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis (2016) 1.41
Scalable Collaborative Infrastructure for a Learning Healthcare System (SCILHS): architecture. J Am Med Inform Assoc (2014) 1.40
Muscle Biopsy Findings in Combination With Myositis-Specific Autoantibodies Aid Prediction of Outcomes in Juvenile Dermatomyositis. Arthritis Rheumatol (2016) 1.40
An i2b2-based, generalizable, open source, self-scaling chronic disease registry. J Am Med Inform Assoc (2012) 1.39
A national registry for juvenile dermatomyositis and other paediatric idiopathic inflammatory myopathies: 10 years' experience; the Juvenile Dermatomyositis National (UK and Ireland) Cohort Biomarker Study and Repository for Idiopathic Inflammatory Myopathies. Rheumatology (Oxford) (2010) 1.29
Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference. Arthritis Care Res (Hoboken) (2012) 1.25
Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies. Rheum Dis Clin North Am (2013) 1.18
Childhood Arthritis and Rheumatology Research Alliance consensus treatment plans for new-onset polyarticular juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) (2014) 1.11
Clinical characteristics of children with juvenile dermatomyositis: the Childhood Arthritis and Rheumatology Research Alliance Registry. Arthritis Care Res (Hoboken) (2014) 0.98
Developing a standardized approach to the assessment of pain in children and youth presenting to pediatric rheumatology providers: a Delphi survey and consensus conference process followed by feasibility testing. Pediatr Rheumatol Online J (2012) 0.83
Juvenile dermatomyositis: new insights and new treatment strategies. Ther Adv Musculoskelet Dis (2012) 0.81
Improving care delivery and outcomes in pediatric rheumatic diseases. Curr Opin Rheumatol (2016) 0.79
Developing a provisional, international minimal dataset for Juvenile Dermatomyositis: for use in clinical practice to inform research. Pediatr Rheumatol Online J (2014) 0.77
Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease. Pediatr Rheumatol Online J (2017) 0.75
Autoimmune neuromuscular disorders in childhood. Curr Treat Options Neurol (2011) 0.75
Current pediatric rheumatology fellowship training in the United States: what fellows actually do. Pediatr Rheumatol Online J (2014) 0.75
Assessment, classification and treatment of calcinosis as a complication of juvenile dermatomyositis: a survey of pediatric rheumatologists by the childhood arthritis and rheumatology research alliance (CARRA). Pediatr Rheumatol Online J (2017) 0.75
Clinical practice variation and need for pediatric-specific treatment guidelines among rheumatologists caring for children with ANCA-associated vasculitis: an international clinician survey. Pediatr Rheumatol Online J (2017) 0.75
Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis Rheum (2004) 2.31
US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum (2003) 2.21
Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatology (Oxford) (2003) 2.18
Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) (2001) 1.96
Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum (2000) 1.91
Defining Clinical Improvement in Adult and Juvenile Myositis. J Rheumatol (2003) 1.75
Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. Arthritis Rheum (2003) 1.71
Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: I. Physician, parent, and patient global assessments. Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Arthritis Rheum (1997) 1.55
DERMATOMYOSITIS. J Pediatr (1964) 1.42
Nominal group technique. A method of decision-making by committee. Anaesthesia (1980) 1.35
The Cutaneous Assessment Tool: development and reliability in juvenile idiopathic inflammatory myopathy. Rheumatology (Oxford) (2007) 1.18
Preliminary validation and clinical meaning of the Cutaneous Assessment Tool in juvenile dermatomyositis. Arthritis Rheum (2008) 1.09
Treatment approaches to juvenile dermatomyositis (JDM) across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey. J Rheumatol (2010) 1.06
Intra-rater and inter-rater reliability of the 10-point Manual Muscle Test (MMT) of strength in children with juvenile idiopathic inflammatory myopathies (JIIM). Phys Occup Ther Pediatr (2006) 1.04
The role of aggressive corticosteroid therapy in patients with juvenile dermatomyositis: a propensity score analysis. Arthritis Rheum (2008) 0.92
Fitting marginal structural models: estimating covariate-treatment associations in the reweighted data set can guide model fitting. J Clin Epidemiol (2008) 0.81
Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med (2008) 4.58
Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant (2006) 4.09
Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. Genome Res (2009) 3.81
Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum (2013) 3.55
A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum (2007) 3.32
Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet (2008) 3.00
Dense genotyping of immune-related disease regions identifies 14 new susceptibility loci for juvenile idiopathic arthritis. Nat Genet (2013) 2.60
Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum (2008) 2.56
Classification criteria in rheumatic diseases: a review of methodologic properties. Arthritis Rheum (2007) 2.41
Asking the experts: exploring the self-management needs of adolescents with arthritis. Arthritis Rheum (2008) 2.40
Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis Rheum (2004) 2.31
Nuclear envelope dystrophies show a transcriptional fingerprint suggesting disruption of Rb-MyoD pathways in muscle regeneration. Brain (2006) 2.22
US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum (2003) 2.21
Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) (2012) 2.21
Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatology (Oxford) (2003) 2.18
Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet (2008) 2.16
Age-related somatic structural changes in the nuclear genome of human blood cells. Am J Hum Genet (2012) 2.15
Shrinking lung syndrome as a manifestation of pleuritis: a new model based on pulmonary physiological studies. J Rheumatol (2013) 2.00
Access to biologic therapies in Canada for children with juvenile idiopathic arthritis. J Rheumatol (2012) 1.97
Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum (2009) 1.94
Rheumatic disease and carotid intima-media thickness: a systematic review and meta-analysis. Arterioscler Thromb Vasc Biol (2010) 1.93
A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum (2006) 1.93
Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma. Arthritis Care Res (Hoboken) (2012) 1.84
Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: a novel model of pathogenesis. J Immunol (2002) 1.83
Predicting the course of juvenile dermatomyositis: significance of early clinical and laboratory features. Arthritis Rheum (2008) 1.81
Measuring process of arthritis care: a proposed set of quality measures for the process of care in juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) (2011) 1.79
An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med (2007) 1.79
Susac's syndrome: 1975-2005 microangiopathy/autoimmune endotheliopathy. J Neurol Sci (2007) 1.76
International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum (2005) 1.75
Defining Clinical Improvement in Adult and Juvenile Myositis. J Rheumatol (2003) 1.75
Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. Arthritis Rheum (2003) 1.71
B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum (2005) 1.71
Increased sensitivity of the European medicines agency algorithm for classification of childhood granulomatosis with polyangiitis. J Rheumatol (2012) 1.70
US findings of metacarpophalangeal joints in children with idiopathic juvenile arthritis. Pediatr Radiol (2007) 1.66
International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum (2004) 1.66
American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) (2011) 1.65
Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken) (2010) 1.65
Comparison of patients with juvenile psoriatic arthritis and nonpsoriatic juvenile idiopathic arthritis: how different are they? J Rheumatol (2009) 1.63
Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis. Arthritis Rheum (2008) 1.60
Methods to elicit beliefs for Bayesian priors: a systematic review. J Clin Epidemiol (2009) 1.59
Effect of warfarin on survival in scleroderma-associated pulmonary arterial hypertension (SSc-PAH) and idiopathic PAH. Belief elicitation for Bayesian priors. J Rheumatol (2010) 1.58
Takayasu arteritis in children and adolescents. Rheumatology (Oxford) (2010) 1.58
Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis Rheum (2005) 1.56
Increased prevalence of familial autoimmunity in probands with pervasive developmental disorders. Pediatrics (2003) 1.56
Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease. Arthritis Rheum (2005) 1.55
Shifting our thinking about uncommon disease trials: the case of methotrexate in scleroderma. J Rheumatol (2009) 1.54
Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage. Arthritis Rheum (2002) 1.52
Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis. Arthritis Rheumatol (2014) 1.51
Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum (2011) 1.51
Predictors of appropriate defibrillator therapy among patients with an implantable defibrillator that delivers cardiac resynchronization therapy. J Cardiovasc Electrophysiol (2006) 1.51
Very high serum ferritin levels are associated with increased mortality and critical care in pediatric patients. Pediatr Crit Care Med (2011) 1.51
Developing standards of care for patients with juvenile idiopathic arthritis. Rheumatology (Oxford) (2010) 1.51
Juvenile rheumatoid arthritis affected sibpairs: extent of clinical phenotype concordance. Arthritis Rheum (2004) 1.50
Clinical and cost implications of target joints in Canadian boys with severe hemophilia A. J Pediatr (2004) 1.50
Chronic minocycline-induced autoimmunity in children. J Pediatr (2008) 1.49
Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis. Nat Rev Rheumatol (2011) 1.48
Mycophenolate mofetil: a possible therapeutic agent for children with juvenile dermatomyositis. Arthritis Care Res (Hoboken) (2010) 1.48
Genetic sophistication of human complement components C4A and C4B and RP-C4-CYP21-TNX (RCCX) modules in the major histocompatibility complex. Am J Hum Genet (2002) 1.47
Increased prevalence of familial autoimmunity in simplex and multiplex families with juvenile rheumatoid arthritis. Arthritis Rheum (2002) 1.47
An internet-based self-management program with telephone support for adolescents with arthritis: a pilot randomized controlled trial. J Rheumatol (2010) 1.47
A new toolkit for conducting clinical trials in rare disorders. J Popul Ther Clin Pharmacol (2014) 1.47
The Quality of My Life questionnaire: the minimal clinically important difference for pediatric rheumatology patients. J Rheumatol (2006) 1.47
HLA-DQA1 is not an apparent risk factor for microchimerism in patients with various autoimmune diseases and in healthy individuals. Arthritis Rheum (2003) 1.46
e-Ouch: usability testing of an electronic chronic pain diary for adolescents with arthritis. Clin J Pain (2006) 1.46
Longterm anticoagulation is preferable for patients with antiphospholipid antibody syndrome. result of a decision analysis. J Rheumatol (2002) 1.44
The role of parenteral lipids in the development of advanced intestinal failure-associated liver disease in infants: a multiple-variable analysis. JPEN J Parenter Enteral Nutr (2011) 1.44
Sinus bradycardia after intravenous pulse methylprednisolone. Pediatrics (2007) 1.44
Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum (2003) 1.42
Double trouble: therapeutic challenges in patients with both juvenile dermatomyositis and psoriasis. Arch Dermatol (2011) 1.41
Old challenges and new directions in pediatric rheumatology. J Rheumatol (2006) 1.40
An i2b2-based, generalizable, open source, self-scaling chronic disease registry. J Am Med Inform Assoc (2012) 1.39
Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. Medicine (Baltimore) (2006) 1.39
Gene expression profiling in human autoimmunity. Immunol Rev (2006) 1.38